Topic: “Science + Commercialization = Valuation. Building a Commercial Story that Resonates with Prospective Partners.”
Speaker: Harris Kaplan, President and Chief Executive Officer, Healogix
Date and Time: Tuesday, Dec.. 8, 2009, 6:00 – 9:00 pm
Location: Location: TIPS Group Law Offices , 1000 Elwell Court, Palo Alto, CA 94303
Advanced registration is required see bio2devicegroup.org website for details a week prior to event.
Cost: Fee for light dinner with range depending on timing of registration:
The biotech IPO window has been closed for some time now and is unlikely to reopen anytime soon. As a result, biotech executives are increasingly reliant on a big pharma or big biotech to provide the capital needed to continue to develop promising new compounds and the competition for pharma or biotech dollars is intense. The larger companies differ significantly from financial investors. They are at least as concerned about how the product will perform in the market post launch as they are about the science. Thus, it is as important for a biotech executive understand the commercialization opportunity and to make that story come to life for an executive. Think venture capital but without a requirement that “monies have to be put to work.” A biotech executive has to make one of these larger companies want to do a deal with your company.
This talk will focus on how biotech executives go about building a robust commercial story – what elements need to be included in that story and how to position compounds so they are very attractive to pharma and big biotech scientists and business development executives. Most biotech deals get one opportunity to present their technology and/or product. This talk will help company executives make that one time count.
Harris Kaplan is currently President and Chief Executive Officer of Healogix, a consultancy formed in late 2005 that advises companies on how to create and maximize the value of new products in development.
Harris has extensive experience in the pharmaceutical industry both on the client and consulting side of the business and has worked on the introduction of more than 75 new products including Lipitor, Crestor, Nexium, Rituxan, and Herceptin.
Harris co-founded Migliara-Kaplan Associates which became the world’s largest custom marketing research company serving 19 of the top 20 pharmaceutical companies. Migliara-Kaplan Associates specialized in helping companies identify new product opportunities and then maximizing the commercial potential of new products in development. Migliara-Kaplan was acquired by NFO in 1996 and is now part of TNS Healthcare. Harris was also cofounder of Cozint Interactive which was acquired by GFK, the German based research company. Harris serves as an advisor to several venture capital funds and is on the Board of Directors of Informedix and the Kernan Orthopedic Hospital.